| Jun 19, 2026 | Virtual cells for target discovery, perturbation models, and benchmarks |
| Jun 12, 2026 | Synthetic lethality and combination targets: ML methods for finding drug pairs that work together |
| Jun 05, 2026 | Knowledge graphs, network medicine, and the first end-to-end AI-discovered drug: a target-discovery case study |
| Jun 03, 2026 | Likelihood of approval, phase transitions, and the crowded-vs-abandoned map of therapeutic areas |
| Jun 03, 2026 | Tissue specificity as a safety filter: GTEx, Human Protein Atlas, and scRNA-seq for target prioritization |
| May 29, 2026 | Novel vs repurposed targets: quantifying novelty and extending drug-repurposing methods |
| May 28, 2026 | Druggability, ligandability, and modality choice in the AlphaFold 3 era |
| May 28, 2026 | How to tell a drug target matters: evidence frameworks for target–disease linkage |
| May 28, 2026 | Drug target discovery: the front-of-funnel decision behind most Phase II failures |